American Society for Bone and Mineral Research-Orthopaedic Research Society Joint Task Force Report on Cell-Based Therapies |
| |
| Authors: | Regis J O'Keefe Rocky S Tuan Nancy E Lane Hani A Awad Frank Barry Bruce A Bunnell Céline Colnot Matthew T Drake Hicham Drissi Nathaniel A Dyment Lisa A Fortier Robert E Guldberg Rita Kandel David G Little Mary F Marshall Jeremy J Mao Norimasa Nakamura Benedikt L Proffen Scott A. Rodeo Vicki Rosen Stavros Thomopoulos Edward M. Schwarz Rosa Serra |
| |
| Affiliation: | 1. Department of Orthopaedic Surgery, School of Medicine, Washington University, St. Louis, MO, USA;2. The Chinese University of Hong Kong, Institute for Tissue Engineering and Regenerative Medicine, Hong Kong SAR, China;3. Department of Medicine, University of California, Davis, CA, USA;4. Department of Biomedical Engineering, Department of Orthopaedics and Rehabilitation, University of Rochester, Rochester, NY, USA;5. Regenerative Medicine Institute, National University of Ireland Galway, Galway, Ireland;6. Department of Pharmacology, School of Medicine, Tulane University, New Orleans, LA, USA;7. INSERM UMR 1163, Imagine Institute, Paris, France;8. Department of Endocrinology, Mayo Clinic, Rochester, MN, USA;9. Department of Orthopaedics, Emory Healthcare, Emory University, Tucker, GA, USA;10. Department of Orthopaedic Surgery, McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA;11. College of Veterinary Medicine, Cornell University, Ithaca, NY, USA;12. Phil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon, Eugene, OR, USA;13. Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada;14. Orthopaedic Research and Biotechnology, Kids Research Institute, Westmead, Australia;15. Center for Biomedical Ethics and Humanities, University of Virginia, Charlottesville, VA, USA;16. Division of Orthodontics, College of Dental Medicine, Columbia University, New York, NY, USA;17. Institute for Medical Science in Sports, Osaka Health Science University, Osaka, Japan;18. Department of Orthopaedic Surgery, Sports Medicine Research Laboratory, Harvard Medical School/Boston Children's Hospital, Boston, MA, USA;19. Hospital for Special Surgery, New York, NY, USA;20. Department of Developmental Biology, Harvard School of Dental Medicine, Harvard University, Boston, MA, USA;21. Department of Orthopedic Surgery, Columbia University, New York, NY, USA;22. Center for Musculoskeletal Research, University of Rochester, Rochester, NY, USA;23. University of Alabama at Birmingham, AL, USA |
| |
| Abstract: | Cell-based therapies, defined here as the delivery of cells in vivo to treat disease, have recently gained increasing public attention as a potentially promising approach to restore structure and function to musculoskeletal tissues. Although cell-based therapy has the potential to improve the treatment of disorders of the musculoskeletal system, there is also the possibility of misuse and misrepresentation of the efficacy of such treatments. The medical literature contains anecdotal reports and research studies, along with web-based marketing and patient testimonials supporting cell-based therapy. Both the American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS) are committed to ensuring that the potential of cell-based therapies is realized through rigorous, reproducible, and clinically meaningful scientific discovery. The two organizations convened a multidisciplinary and international Task Force composed of physicians, surgeons, and scientists who are recognized experts in the development and use of cell-based therapies. The Task Force was charged with defining the state-of-the art in cell-based therapies and identifying the gaps in knowledge and methodologies that should guide the research agenda. The efforts of this Task Force are designed to provide researchers and clinicians with a better understanding of the current state of the science and research needed to advance the study and use of cell-based therapies for skeletal tissues. The design and implementation of rigorous, thorough protocols will be critical to leveraging these innovative treatments and optimizing clinical and functional patient outcomes. In addition to providing specific recommendations and ethical considerations for preclinical and clinical investigations, this report concludes with an outline to address knowledge gaps in how to determine the cell autonomous and nonautonomous effects of a donor population used for bone regeneration. © 2019 American Society for Bone and Mineral Research. |
| |
| Keywords: | ANIMAL MODELS CELL/TISSUE SIGNALING, TRANSCRIPTION FACTORS CELLS OF BONE CLINICAL TRIALS GENETIC RESEARCH |
|
|
